KM102
Dry Eye Disease
Pre-clinicalActive
Key Facts
About Theratome Bio
Theratome Bio is a private, pre-revenue biotech company founded in 2018, transitioning from research to commercial focus in 2023. Its core technology involves AI-optimized, second-generation secretomes derived from adult stem cells, engineered for specific disease profiles by enhancing desired components and deleting others. The company's near-term pipeline targets organ transplant preservation and dry eye disease, with a longer-term interest in conditions like ARDS, ALS, and stroke, led by a team with deep expertise in vascular biology and cell therapy.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Elate Ocular® | Cambium Bio | Phase 3 |
| OT-301 | Ocumension Therapeutics | Phase 2 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| HydraD | EyeD Pharma | Pre-Clinical |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |
| BRM421 | BRIM Biotechnology | Phase 3 |